Skip to main content

Kiromic BioPharma, Inc. (KRBP)

NASDAQ: KRBP · IEX Real-Time Price · USD
1.93
+0.01 (0.52%)
After-hours:Oct 22, 2021 6:32 PM EDT
1.92
-0.09 (-4.48%)
At close: Oct 22, 4:00 PM
Market Cap32.03M
Revenue (ttm)n/a
Net Income (ttm)-14.81M
Shares Out7.35M
EPS (ttm)-2.24
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume117,345
Open2.03
Previous Close2.01
Day's Range1.86 - 2.09
52-Week Range1.81 - 18.50
Betan/a
Analystsn/a
Price Targetn/a
Est. Earnings DateNov 12, 2021

About KRBP

Kiromic BioPharma, Inc., a target discovery and gene editing company, focuses on developing immuno-oncology therapeutics for the treatment of blood cancers and solid tumors. The company develops ALEXIS-ISO-1, an allogenic gamma delta CAR-T cell therapy product candidate targeting Isomesothelin; ALEXIS-PRO-1, an allogeneic gamma delta chimeric T cell therapy product candidate targeting PD-L1; and chimeric gamma delta PD1 T cell switch receptor therapy. It has license agreements with Mercer University; CGA 369 Intellectual Holdings, Inc.; and Lon...

IndustryBiotechnology
IPO DateOct 16, 2020
Employees19
Stock ExchangeNASDAQ
Ticker SymbolKRBP
Full Company Profile

Financial Performance

Financial Statements

News

Kiromic BioPharma Announces Strategic Collaboration with Gemelli Teaching Hospital to Accelerate the Analysis of Allo...

HOUSTON--(BUSINESS WIRE)---- $KRBP #KRBP--Kiromic BioPharma Announces Strategic Collaboration with Gemelli Teaching Hospital

1 week ago - Business Wire

Kiromic BioPharma Announces Chief Financial Officer Transition

HOUSTON--(BUSINESS WIRE)---- $KRBP #KRBP--Kiromic BioPharma Announces Chief Financial Officer Transition

2 weeks ago - Business Wire

Kiromic BioPharma Reports Second Quarter 2021 Financial Results and Operating Highlights

HOUSTON--(BUSINESS WIRE)---- $KRBP #KRBP--Kiromic BioPharma Reports Second Quarter 2021 Financial Results and Operating Highlights

2 months ago - Business Wire

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Kiromic BioPharma, Inc. - KRBP

NEW YORK, July 28, 2021 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Kiromic BioPharma, Inc. ("Kiromic" or the "Company") (NASDAQ: KRBP). Such investors are advised to...

2 months ago - PRNewsWire

Kiromic Announces the Acquisition of InSilico Solutions Leveraging on Bioinformatics and Artificial Intelligence to A...

HOUSTON--(BUSINESS WIRE)---- $KRBP #KRBP--Kiromic announces the acquisition of InSilico Solutions leveraging on Bioinformatics and Artificial Intelligence to advance clinical development

2 months ago - Business Wire

Kiromic BioPharma Provides Update on IND Filings on its Off-the-Shelf, Allogeneic CAR-T for Solid Tumors

HOUSTON--(BUSINESS WIRE)---- $KRBP #KRBP--Kiromic BioPharma Provides Update on IND Filings on its Off-the-Shelf, Allogeneic CAR-T for Solid Tumors

3 months ago - Business Wire

Kiromic BioPharma, Inc. Announces Closing of Public Offering

HOUSTON--(BUSINESS WIRE)---- $KRBP #KRBP--Kiromic BioPharma, Inc. Announces Closing of Public Offering

3 months ago - Business Wire

Kiromic BioPharma Stock Plunges After $40M Equity Raise Issued At 24% Discount

Kiromic BioPharma Inc (NASDAQ: KRBP) has priced an underwritten public offering of 8 million shares at $5.00 per share, for gross proceeds of $40 million. The offer price is at a 24% discount on the las...

3 months ago - Benzinga

Kiromic BioPharma, Inc. Announces Pricing of Public Offering

HOUSTON--(BUSINESS WIRE)---- $KRBP #KRBP--Kiromic BioPharma, Inc. Announces Pricing of Public Offering

3 months ago - Business Wire

KRBP Presenting at 2021 Next-Gen Immuno Oncology Congress Showcasing Its Proprietary AI Targets for Off-the-Shelf All...

HOUSTON--(BUSINESS WIRE)---- $KRBP #KRBP--KRBP Presenting at 2021 Next-Gen Immuno Oncology Congress Showcasing Its Proprietary AI Targets for Off-the-Shelf Allogenic CAR-T for Solid Tumors

3 months ago - Business Wire

KRBP Presenting at July 2021 Gamma Delta T Cell Summit to Showcase Our Off-The-Shelf Allogeneic Gamma Delta T Cell Th...

HOUSTON--(BUSINESS WIRE)---- $KRBP #KRBP--KRBP Presenting at July 2021 Gamma Delta T Cell summit to Showcase Our Off-The-Shelf Allogeneic Gamma Delta T Cell Therapy

4 months ago - Business Wire

Kiromic Announces Expansion of In-House Cell therapy cGMP Manufacturing Facility and the Appointment of Industry Vete...

HOUSTON--(BUSINESS WIRE)---- $KRBP #KRBP--Kiromic Announces Expansion of In-House Cell therapy cGMP Manufacturing Facility and the Appointment of Industry Veteran Ignacio Núñez as COMO

4 months ago - Business Wire

Kiromic Announces FDA IND Submission First-In-Human, AI derived Off-The-Shelf IsoMesothelin Gamma Delta CAR T-cell Th...

HOUSTON--(BUSINESS WIRE)---- $KRBP #IND--Kiromic Announces FDA IND Submission First-In-Human, AI derived Off-The-Shelf IsoMesothelin Gamma Delta CAR T-cell Therapy

4 months ago - Business Wire

Kiromic Announces Identification of Novel Targets for Allogeneic CAR Gamma Delta T-cell Therapy in Solid Tumors Utili...

HOUSTON--(BUSINESS WIRE)---- $KRBP #AI--Kiromic announces Identification of Novel Targets for Allogeneic CAR Gamma Delta T-cell Therapy in Solid Tumors Utilizing Proprietary AI Engine

5 months ago - Business Wire

Kiromic Announces FDA IND Submission Forty-Five Days before the end of the Second Quarter: First-In-Human, Off-The-Sh...

HOUSTON--(BUSINESS WIRE)---- $KRBP #INDSubmission--Kiromic Announces FDA IND Submission Forty-Five Days before the end of the Second Quarter

5 months ago - Business Wire

Kiromic BioPharma Reports First Quarter 2021 Financial Results and Continued Corporate Progress

HOUSTON--(BUSINESS WIRE)---- $KRBP #KRBP--Kiromic BioPharma Reports First Quarter 2021 Financial Results and Continued Corporate Progress

5 months ago - Business Wire

Kiromic Announces 6 Posters Presented at American Association of Cancer Research 2021 Showcasing our Artificial Intel...

HOUSTON--(BUSINESS WIRE)---- $KRBP #KRBP--Kiromic Announces 6 Posters Presented at American Association of Cancer Research 2021 Showcasing our Artificial Intelligence (AI) Biomarker Engine

5 months ago - Business Wire

Kiromic BioPharma Reports Fiscal Year 2020 Financial Results and Continued Corporate Progress

HOUSTON--(BUSINESS WIRE)---- $KRBP #KRBP--Kiromic BioPharma Reports Fiscal Year 2020 Financial Results and Continued Corporate Progress

6 months ago - Business Wire

Kiromic BioPharma, Inc. Interview to Air on Bloomberg Television U.S. on the RedChip Money Report

HOUSTON--(BUSINESS WIRE)---- $KRBP #KRBP--Kiromic BioPharma, Inc. Interview to Air on Bloomberg Television U.S. on the RedChip Money Report

6 months ago - Business Wire

Kiromic to Resubmit Two Expanded INDs to the FDA for Its Allogenic, Off-the-Shelf Gamma-Delta T cell Therapies for Mu...

HOUSTON--(BUSINESS WIRE)--Kiromic Biopharma, Inc. (Nasdaq: KRBP), a target discovery and gene-editing company utilizing artificial intelligence and its proprietary neural network platform with a therape...

7 months ago - Business Wire

Kiromic Announces License Agreement With Longwood University for chPD1

HOUSTON--(BUSINESS WIRE)--Kiromic BioPharma, Inc. (Nasdaq: KRBP), an immuno-oncology target discovery and gene-editing company, with a proprietary artificial intelligence neural network platform (Diamon...

8 months ago - Business Wire

Kiromic Announces the Completion of its GMP Manufacturing Facility in Houston, Texas, to Support the Manufacturing of...

HOUSTON--(BUSINESS WIRE)--Kiromic BioPharma, Inc. (Nasdaq: KRBP), an immuno-oncology target discovery and gene-editing company, with a proprietary artificial intelligence neural network platform (Diamon...

9 months ago - Business Wire

Kiromic Announces the Filing of Key European Patents for Its Chimeric PD-1 (chPD1) Target

HOUSTON--(BUSINESS WIRE)--Kiromic Biopharma, Inc. (Nasdaq: KRBP), a target discovery and gene-editing company utilizing artificial intelligence and proprietary neural network platform with a therapeutic...

9 months ago - Business Wire

Kiromic Announces Submission of Two IND Applications for PD1 Gamma-delta CAR - T cell Therapy with the FDA

HOUSTON--(BUSINESS WIRE)--Kiromic BioPharma (“the Company”) (NASDAQ: KRBP), a target discovery and gene-editing company utilizing artificial intelligence and its proprietary neural network platform with...

10 months ago - Business Wire

Kiromic BioPharma Reports Third Quarter 2020 Financial Results and Continued Corporate Progress

HOUSTON--(BUSINESS WIRE)--Kiromic BioPharma (“the Company”) (NASDAQ: KRBP), a pre-clinical stage biotechnology company using its proprietary DIAMOND® artificial intelligence (“A.I.”) platform to improve...

10 months ago - Business Wire